Overview

Randomized Evaluation of Anagliptin Versus Sitagliptin On Low-density lipoproteiN Cholesterol in Diabetes Trial

Status:
Completed
Trial end date:
2019-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether Anagliptin or Sitagliptin are effective in reducing the low-density lipoprotein cholesterol in patients with type 2 diabetes and cardiovascular risk factors on statin.
Phase:
Phase 4
Details
Lead Sponsor:
Institute for Clinical Effectiveness, Japan
Treatments:
Anagliptin
Sitagliptin Phosphate